CELL INTELLIGENCE · 肿瘤细胞治疗研究

溶瘤寨卡病毒疗法利用 CCR2+ 单核细胞增强抗胶质母细胞瘤的 T 细胞应答

Oncolytic zika virus therapy leverages CCR2+ monocytes to boost anti-glioblastoma T cell responses.

ZIKV 驱动的 CCR2+单核细胞活化和募集通过增强细胞毒性和限制耗竭，支持强效的抗肿瘤 CD8+ T 细胞应答。这些发现凸显了调节单核细胞-T 细胞交互作用以克服 GBM 中免疫抑制此前未被认识的治疗潜力。

打破胶质母细胞瘤的免疫隔离

Breaking immune isolation in glioblastoma.

胶质母细胞瘤的下一代治疗：挑战与未来方向

Next-generation therapeutics for glioblastoma: Challenges and future directions.

开发基于溶瘤病毒递送 CD19 和 EGFRvIII 抗原与双特异性 CAR 的胶质母细胞瘤多模式治疗

Developing a multimodal therapy for glioblastoma using oncolytic virus delivering CD19 and EGFRvIII antigens and bi-specific CARs.

H3 K27 变异型弥漫性中线胶质瘤时代的弥漫性内生性脑桥胶质瘤

Diffuse intrinsic pontine glioma in the era of H3 K27-altered diffuse midline glioma.

代谢依赖性与神经祖细胞失调：儿童高级别胶质瘤发生的驱动力

Metabolic dependencies and neural progenitor dysregulation: driving forces in paediatric high-grade glioma development.

弥漫性内生性脑桥胶质瘤的免疫抑制性肿瘤微环境与治疗现状

Immunosuppressive Tumor Microenvironment and Therapeutic Landscape of Diffuse Intrinsic Pontine Glioma.

胶质瘤免疫治疗：耐药和合理联合设计的区室框架

Immunotherapy for Glioma: A compartmental framework for resistance and rational combination design.

临床试验中单次溶瘤病毒治疗后 T 细胞对胶质母细胞瘤的持续激活和细胞毒性

Persistent T cell activation and cytotoxicity against glioblastoma following single oncolytic virus treatment in a clinical trial.

推进胶质母细胞瘤 CAR-T 细胞疗法前沿：从临床障碍到突破性策略的现状探索

Advancing chimeric antigen receptor T-cell therapy frontiers in glioblastoma: Navigating the current landscape from clinical hurdles to breakthrough s